GlassScriptPhysician profile
Harshit Khosla
NPI 1881207256
$1,423.37
in general payments reported to CMS, 2019-2025
18 companies · $295 in 2025
The $295 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $334 · 2022: $363 · 2023: $263 · 2024: $168 · 2025: $295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $726.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $327.32 | 2021-2025 | Opdivo, Camzyos |
| Abbvie INC. | $181.04 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $137.85 | 2021-2024 | Lynparza |
| Janssen Biotech, INC. | $124.14 | 2024-2025 | Carvykti, Rybrevant, Erleada |
| Helsinn Therapeutics (U.S.), INC. | $95.62 | 2022 | |
| Janssen Pharmaceuticals, INC | $79.38 | 2021-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.34 | 2021-2022 | |
| Pfizer INC. | $68.20 | 2021-2023 | |
| Genmab U.S., INC. | $60.90 | 2024-2025 | Epkinly |
| Takeda Pharmaceuticals U.S.A., INC. | $51.73 | 2021 | |
| Alexion Pharmaceuticals, INC. | $51.38 | 2021-2023 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $39.04 | 2022-2023 | |
| Lilly USA, LLC | $32.44 | 2025 | Verzenio, Jaypirca |
| Alcresta Therapeutics, INC. | $24.44 | 2022 | |
| Merck Sharp & Dohme LLC | $23.48 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $18.41 | 2023 | |
| Fresenius Kabi USA, LLC | $15.83 | 2023 | |
| Glaxosmithkline, LLC. | $13.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harshit Khosla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.